From: Thymostimulin in advanced hepatocellular carcinoma: A phase II trial
Characteristics (n = 44) | |
---|---|
Patients | |
Male/female, n (%) | 37/7 (84/16) |
Median age, years (range) | 69 (41–80) |
Median weight, kg (range) | 74 (58–123) |
Origin of liver disease, n (%) | |
Alcohol abuse | 20 (46) |
HBV/HCV | 8 (18) |
NASH | 5 (11) |
Cryptogenic | 11 (25) |
Tumor stage, n (%) | |
Liver cirrhosis | 37 (84) |
Child classification A/B/C | 23/9/5 (52/21/11) |
Okuda stage I/II/III | 13/28/3 (29/64/7) |
CLIP 0/1–3/4–6 | 2/35/7 (5/79/16) |
α-FP (ng/ml), n (%) | |
< 400 | 29 (66) |
400- 10000 | 8 (18) |
> 10000 | 7 (16) |
Tumor characteristics, n (%) | |
Ascites | 13 (30) |
Portal vein thrombosis | 14 (32) |
Multifocal tumor manifestation | 38 (86) |
Extrahepatic metastases | 9 (21) |
Previous treatment, n (%) | |
(combination possible) | |
Surgery | 4 (9) |
Radiofrequency ablation | 5 (11) |
Transarterial chemoembolisation | 17 (39) |
Systemic chemotherapy | 4 (9) |